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Abstract: Glioma remains the most challenging solid organ tumor to treat successfully. 
Based on the capacity of stem cells to migrate extensively and target invading glioma cells, the 
  transplantation of stem cells as a cell-based delivery system may provide additional tools for the 
treatment of gliomas. In addition to the use of modified stem cells for the delivery of therapeutic 
agents, unmodified stem cells have been shown to have growth-suppressing effects on tumors 
in vitro and in vivo. This review outlines the probable factors involved in tumor tropism and 
tumor growth suppression, with a specific focus on the use of unmodified stem cells in the treat-
ment of gliomas. Based on these and further future data, clinical trials may be justified.
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Introduction
Glioma is the most common type of human primary brain tumor. Malignant gliomas 
constitute 22%–27% of all brain tumors.1 In spite of many technological advances in 
neurosurgery, neuroimaging, radiation therapy, and chemotherapy, the prognosis for 
patients with malignant gliomas is poor. The highly infiltrative nature of glioma cells 
is the major cause of their dismal prognosis. The glioma cells migrate from the core 
mass and produce secondary, microsatellite tumors in normal brain parenchyma.2
Removal of microsatellite tumors by surgery is not feasible, and these tumors 
are the seeds for recurrent tumor growth.3 Invasiveness is regulated by the interplay 
between secreted proteases (eg, cathepsins) and their endogenous inhibitors (cystatins). 
Cystatin E/M is a potent inhibitor of cathepsin B, which is frequently overexpressed 
in gliomas.4
One of the therapeutic strategies to treat glioma is the eradication of invading 
glioma cell microsatellite tumors before they develop into recurrent tumors.5 Some 
reports have shown that neural stem cell (NSC) transplantation may be useful in treating 
several central nervous system (CNS) diseases or injuries. Several groups have used 
NSCs to treat tumors that affect the CNS.6–9
The presence of tumor signals may influence the behavior of NSCs by virtue 
of their inherent migratory and tumor-trophic properties. This ability represents a 
new and potentially powerful approach in the treatment of invasive tumors and has 
been used as a delivery vehicle for targeting and disseminating therapeutic gene 
  products throughout tumor sites. NSCs, by infiltrating the tumor mass selectively and 
aggressively, may help to overcome major obstacles that are being faced by current 
gene therapy strategies.2,10,11Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Brain tumor tropism of NSCs can be used to deliver 
therapeutic molecules, such as genes, proteins, peptides, or 
small chemical molecules; however, clinical use of NSCs is 
limited by both ethical and logistical problems, including 
their isolation and their immunological compatibility in 
allogenic transplantation.12,13 Therefore, it is essential to 
find new sources of easily accessible stem cells with tumor-
targeting properties which are also useful for autologous 
transplantation.
The factors involved in brain tumor tropism of NSCs, 
and the interactions of NSCs within the tumor environment, 
are not well known.2 From the perspective of viewing stem 
cell biology as a means to track and help in the eradication 
of tumors, we have reviewed the literature to highlight the 
information on the mechanism of organization, regulation, 
and function of stem cell tropism and tumor growth 
suppression in glioma brain tumors. At this point nearly all 
of the data are limited to in vitro and animal studies and there 
is no evidence of clinical trials.
Stem cell administration, fate  
and distribution around gliomas
It has been shown that stem cells exhibit extensive tropism 
toward tumor sites and infiltrate tumor foci when implanted 
intraventricularly and intracranially within normal tissue on 
the side of a lesion, into the contralateral hemisphere, and 
through the peripheral, intravascular circulation.14–16
Intravascular delivery of stem cells is advantageous 
because it obviates invasive surgical interventions and 
because repeated injections over an extended period are 
clinically feasible. In the study by Nakamizo et al, injection of 
IFN-β from human mesenchymal stem cells into the internal 
carotid artery significantly increased survival of animals 
bearing established intracranial gliomas.15 Interestingly, 
the authors found that when human mesenchymal stem 
cells (hMSCs) were injected into tail veins, the majority of 
stem cells were filtered by the lungs. Brown et al have 
suggested that intravascular administration of NSCs was an 
effective delivery vehicle for targeting and disseminating 
therapeutic agents to invasive tumors of neural and nonneural 
origin, both within and outside the brain.17 Tang et al 
showed that most NSCs migrate to the brain tumor through 
an intraventricular path.16 Based on the study by Kim et al, 
50 minutes after contralateral hemispheric NSC injection, 
around 10% of the NSCs migrated to the tumor region. Five 
days after injection, the number of NSCs increased slowly, 
reaching a significant increase by 15 days post-injection. 
Changes in tumor volume showed similar patterns. The rate 
of NSC migration was approximately 175 µm/min. In the 
absence of in vivo tumor cell inoculation, the number of 
NSCs increased approximately 1.7-fold during day one; 
however, the proliferation of NSCs began to decrease 5 days 
after injection.18
Nakamizo et al found that the intratumoral injection of 
2.5 × 104 hMSCs did not extend animal survival. Based on 
this, they concluded that at least 25% of cells (2.5 × 105 
hMSCs interferon [IFN]-β) must have integrated into the 
tumor for a significant increase in animal survival, so intra-
arterial injection of at least 1 × 106 hMSCs is needed.15 
Although the beneficial effects of different stem cells have 
been shown in animal models to some extent, the most effec-
tive type of stem cell, the more convenient and efficient route 
of delivery and the optimal number of stem cells in treatment 
of gliomas have not yet been elucidated and require further 
research.
Mechanism of stem cell migration 
toward gliomas
Although the brain is completely formed and integrated a 
few weeks after birth, it maintains some degree of plasticity 
throughout life, including axonal remodeling, synaptogenesis, 
neural cell birth, migration, and integration. The dentate 
gyrus (DG) of the hippocampus and the subventricular 
zone (SVZ) are the two main neurogenic niches in the adult 
brain. Neural stem cells live in these structures and produce 
progenitors that migrate toward their ultimate locations, 
including the granular cell layer of the DG and olfactory 
bulb, respectively.19 However, the vast majority of adult 
glial progenitors reside outside the neurogenic niches (DG 
and SVZ). Under normal circumstances, these resident adult 
progenitors and their glial progeny do not migrate, although 
they can be stimulated to migrate under pathological 
conditions.19–21
The role of NSCs in both the physiological and patho-
logical processes in the brain has not been clearly explained. 
Normal NSCs possess the capability to migrate extensively 
toward the tumor mass and to linger in and around neoplastic 
regions of the brain.10 The tropism of NSCs toward brain 
tumors may provide an additional tool for the treatment 
of malignant brain tumors. The creation of potential NSC-
based therapies has been studied, and this type of therapy 
involves the delivery of gene products to specific areas of the 
CNS that can selectively target malignant brain tumor cells 
and maximize the capability of their delivery.12,14
Many brain tumor behaviors unexpectedly resemble 
the intrinsic properties of neural stem/progenitor cells.22,23 Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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This has generated recent concern about providing stem 
cells to help eliminate tumors. There is also concern about 
the fact that stem cell biology may be somehow integral to 
the origination and/or production of the neoplasm itself. 
Yet, based on the unrivalled efficiency of NSCs to migrate 
throughout the brain and target invasive tumors, the 
transplantation of NSCs offers a new potential therapeutic 
approach as a cell-based delivery system for gene therapy in 
brain tumors. On the one hand, both stem cells and cancer 
cells are thought to be capable of unlimited proliferation. Yet, 
on the other hand, many tumors and cancer cell lines express 
stem cell markers, suggesting that either cancer cells look like 
stem cells or those cancers contain stem-like cells.22,24,25
During development or after xenograft inoculation, 
  normal NSCs also display high levels of motility throughout 
the brain.26,27 This property is especially discernible when 
NSCs are inoculated immediately after injury.8,28 or during 
tumorigenesis.9,29 Such findings provide evidence that NSCs 
and brain tumor stem cells may respond to migratory signals 
in similar ways.22
Cell migration is an important multistep process that leads 
to organism development, tissue repair, and regeneration. 
In addition, it drives disease progression in cancer and 
inflammation.30 Every step of the cell migration process 
relates to extracellular factors that act on the cell itself 
through molecular pathways and intracellular signaling 
cascades.2
In normal brains, secreted proteins, which act as 
chemoattractants or chemorepellants, coupled with proteins 
that are implicated in cell–cell or cell–matrix interactions, 
play   pivotal roles in the regulation of neural progenitor cell 
migration. In addition, recent data suggest that gliomas 
originate from the transformation of neural stem cells 
or progenitor cells,24,31–33 and that glioma cell infiltration 
reiterates key aspects of glial progenitor migration. The 
factors that are implicated in such cell migrations and 
recruitments are just beginning to be understood. Many 
observations show that brain lesions and neurological 
diseases provoke neural stem/progenitor cell migration 
toward altered structures, such as tumors. Inflammation, 
which has long been contemplated as thoroughly devastating 
to brain repair, is now known to produce some positive effects 
on stem/progenitor cell recruitment through the regulation 
of growth factor signaling and the secretion of a number of 
chemoattractant cytokines. This knowledge is critical for the 
development of new therapeutic strategies.19
Cytokines, such as vascular endothelial cell growth 
factors (VEGFs), tumor growth factors (TGFs), epidermal 
growth factors (EGFs), platelet-derived growth factors 
(PDGF), monocyte chemoattractant protein-1 (MCP-1), and 
interleukin-8 (IL-8), which are released from the neoplasm 
or inflammatory tissues, are all possible candidates for 
tropism of stem cells.34–36 Mesenchymal cells augment 
VEGF-induced angiogenesis in vitro.37 It is recognized that 
the factors released from cancer cells promote the movement 
of endothelial cell progenitors and stromal cell progenitors 
from the bone marrow toward the tumor38,39 or tissues 
surrounding the tumor, which enhances the formation of 
tumor-stroma.40
Gondi et al have observed that human umbilical cord 
blood stem cells (hUCBs) show tropism toward glioma 
cells in vitro, in vivo, and ex vivo. They concluded that this 
migration relies partially on the expression levels of platelet-
derived growth factor-D (PDGF-D) from glioma cells. These 
investigators have also pointed out that a local concentration 
gradient of PDGF-D is sufficient to cause migration of 
hUCBs toward brain slice cultures.41
NSC tumor tropism
NSCs show extensive tropism toward the tumor itself or 
toward the CNS degeneration. In vitro studies have shown 
that NSCs did not migrate toward sites where a needle was 
inserted to imitate tissue damage that takes place during 
the establishment of a tumor bed, but where the actual 
implantation of glioblastoma cells did not take place.10 This 
suggests that the tumor itself possesses at least some of the 
tropic cues necessary to cause NSC migration. Nonetheless, 
in other previously reported experimental situations in which 
significant neuronal death took place.42 NSC differentiation 
was altered by apparent trophic influences. Therefore, the 
signals to which the NSCs respond are most likely complex, 
from multiple sources, and may represent a mixture of 
attractants, adhesion molecules, substrate molecules and 
chemokines of broader biological significance. These findings 
suggest that migration can be unexpectedly extensive, even 
in an adult brain, and along non-stereotypical routes, if 
pathology (ie, a tumor) is present.10 Little is known about the 
signals and factors that influence the tumor tropism of NSCs 
or their interactions within the tumor environment. It has been 
speculated that soluble factors, which are over-expressed by 
tumor cells, may be an important signal for the long-range 
attraction of NSCs from distant sites.
Some empirical evidence indicates that upregulation of 
stromal cell-derived factor (SDF-1)43 and VEGF35 serve as 
soluble chemotactic factors that induce NSC tropism toward 
gliomas; however, the observation that even microsatellites Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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and infiltrating glioma cells that are distant from the main 
tumor mass are targeted by NSCs suggests that additional 
local signals exist that guide NSCs. The migration of 
glioma cells during invasion is associated with a complex 
and   continuous remodeling of the pre-existing normal 
extracellular matrix (ECM) of the brain.44 In vitro and in vivo 
studies have shown that unlike the pre-existing normal ECM, 
the ECM of gliomas and their migration pathways consist 
mainly of tenascin, fibronectin, laminin, vitronectin, and 
different types of collagen.44–47
Laminin, fibronectin, tenascin-C, and collagen I are 
  localized within the basement membrane of existing and newly 
formed blood vessels.44 These basement membrane proteins, 
which comprise the reconstituted basement   membrane Matri-
gel™ (BD Biosciences, Franklin Lakes, NJ), allowed the migra-
tion of HB1.F3-hNSCs in monolayer migration assays.2
The ECM is extensively modified when gliomas progress 
and invade the brain. Ziu et al2 analyzed the effects of 
tumor-ECM compounds from six glioblastoma cell lines on 
NSC motility. They found that NSC migration was highly 
dependent on tumor-produced ECM. Laminin and tenascin-C 
were the most permissive and the strongest inducers of human 
NSC migration, respectively. Different components of ECM 
produced by glioma cells positively affect the degree of 
NSC adhesion and migration. They also suggested that NSC 
migration is modulated by the ECM of malignant gliomas. 
These findings showed that the ECM plays a crucial role 
in NSC migration toward tumor cells, which reinforced 
the idea that cell migration is a complex process. This is 
further supported by the fact that the migratory rate of HB1.
F3-hNSCs on normal Matrigel was significantly higher than 
on growth factor-depleted Matrigel.2
HMSC tumor tropism
Nakamizo et al concluded that the cell-specific capacity of 
hMSCs to localize in human gliomas seems to be an intrinsic 
property of this cell type. The results from this study indicate 
that migration of hMSCs toward glioma tumors may be 
mediated, at least in part, by growth factors and chemokines; 
however, this group showed that despite the presence of a wide 
range of growth factors within tumors, there is selectivity of 
hMSCs for specific factors. For example, whereas fibroblast 
growth factor (FGF) and VEGF had little effect on hMSC 
migration, PDGF, EGF, and SDF-1a enhanced hMSC tropism. 
Moreover, a cocktail of antibodies that block PDGF-BB, EGF, 
and SDF-1a was able to attenuate the migration of hMSCs 
toward conditioned medium derived from U87 cells.15
Nakamura et al showed that cultured rat glioma cells 
stimulate the migration of rat MSCs.48 Soluble factors 
released from 9 L glioma cells mediated the activation of 
MSC migration. Cytokines, such as hepatocyte growth 
factor (HGF),36 VEGF37,49 TGFs,36,37,49,50 FGFs,36 PDGF,36,51 
MCP-1, and IL-8,52,53 which are released from the neoplasm 
or inflammatory tissues, are all possible candidates. These 
factors, which are secreted from cancer cells, encourage the 
migration of endothelial cell progenitors and stromal cell 
progenitors from the bone marrow toward the cancer bed or 
tissue surrounding the tumor and enhance the formation of 
tumor-stroma. Similar mechanisms would be expected for the 
migration of implanted MSCs and tumor-stromal   formation 
in gliomas. Rat MSCs introduced into tumors were basically 
distributed at the border zones between normal rat brain 
parenchyma and tumors.48
In vitro Matrigel invasion assays showed that conditioned 
media from gliomas, but not from fibroblasts or astrocytes, 
supported the migration of hMSCs, and that PDGF, EGF, 
or SDF-1a, but not basic FGF or VEGF, enhanced hMSC 
migration.15
In order to evaluate the capability of hMSCs to track 
human gliomas, Nakamizo et al injected hMSCs directly into 
the opposite side of the cerebral hemisphere of an established 
human glioma and showed that the hMSCs were capable of 
migrating into the xenograft.15 hMSCs may integrate into 
glioma tumors to contribute to the mesenchymal elements of 
the tumor and differentiate into glial and neuronal cells.54,55 
Despite the fact that hMSCs may provide a microenvironment 
that is favorable for tumor growth, they may also have the 
capacity as a cellular vehicle for delivery of therapeutic 
agents to glioma tumors. Further explanation of the 
fundamental mechanism of hMSCs tropism toward gliomas 
may give insights into methods that can be used to increase 
the efficiency of the engraftment process.15
Modified stem cell therapy
By using genetically modified stem cells to secrete anti-
neoplastic compounds, it may be possible to achieve high 
levels of one or more chemotherapeutic agents at the site 
of a tumor.
Different approaches are being undertaken by several 
researchers, all of whom are focusing on a variety of 
potentially therapeutic genes that could exert better   
efficacy with fewer side effects when expressed in close 
proximity to the tumor mass. Antineoplastic compounds 
have been divided into three categories, including the   Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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prodrug-converting enzymes, viral vectors, and immune-
response modulators.14
Genetic strategies are also being developed to deliver 
genetically engineered NSCs to the sites of brain tumors. 
  Candidate genes include those that encode proteins that induce 
differentiation of neoplastic cells and/or their signal transduc-
tion mediators, cell cycle modulators, apoptosis-  promoting 
agents, antiangiogenesis factors, immune-enhancing agents, 
and oncolytic factors.10,56
Lee et al evaluated the therapeutic efficacy of genetically 
modified NSCs encoding cytosine deaminase (CD) and 
IFN-β, a proinflammatory cytokine gene, in treating brain 
stem gliomas. They added 5-fluorocytosine to kill   dividing 
cells, including human NSCs encoding CD and IFN-β. 
  Histological analyses showed a 59% reduction in tumor 
  volume in the treated group, and apoptosis was 2.33-fold 
higher in the treated group than in the control group.57 The 
therapeutic actions of CD and IFN-β are different. CD acts as 
prodrug-activating enzyme and IFN-β has the   antiangiogenic 
effect and immune response.58 Nearly the same gene therapy 
with human NSCs had significant therapeutic benefit in 
experimental gliomas.59 In another study, NSCs were 
  modified to produce CD. Administration of these NSCs 
caused an 80% reduction in tumor masses when animals were 
treated with the systemic prodrug 5-fluorocytosine.17
Antitumor effects of intracranial administration of gene 
modified NSC expressing IL-4,12 IL-12,7 or tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL)6 have also 
been reported.
Gene modification of MSCs by infection with an 
adenoviral vector encoding human IL-2 clearly augmented 
the antitumor effect and further prolonged the survival of 
tumor-bearing rats.48
In experimental glioma models, Nakamizo et al found 
that hMSCs that were engineered to produce IFN-β would 
provide a high degree of local intratumoral delivery, with a 
limited degree of systemic toxicity. They used an adenoviral 
vector to transfer the IFN-β gene into hMSCs and found that 
these engineered hMSCs (hMSC IFN-β) released high levels 
of IFN-β and were capable of directly killing human glioma 
cell lines that were grown in vitro. These studies provided the 
proof of principle that hMSCs can be engineered to release a 
soluble factor into brain tumors. The authors suggested that 
IFN-β is itself a good therapeutic agent worthy of assessment 
in patients with gliomas. The same approach can be exploited 
in the delivery of other agents with antitumor activity. 
  Methods to maximize transfection of therapeutic genes to 
hMSCs and to separate transfected from nontransfected cells 
are challenges for the ultimate application of this and other 
stem cell approaches to treating tumors.15 Although their 
studies have focused on bone marrow-derived hMSCs, Lee 
et al have suggested that other cells in the bone marrow may 
also be useful as delivery vehicles for brain tumors.29
Using live imaging and tumor measurements, Goren et al 
reported that encapsulated hMSC-PEX (Pexin) injected 
next to glioblastoma tumors in nude mice significantly 
reduced tumor volume (87%) and weight (83%). The authors 
clearly demonstrated that hMSCs are the best cell type for 
  microencapsulation cell-based therapy, which brought this 
technology closer to clinical application.60
Germano et al showed that modified embryonic stem cells 
expressing transgenic hTRAIL induced apoptosis in human 
malignant glioma cells while sparing normal cells.61
All of the above observations imply that modified stem 
cells carrying therapeutic genes may successfully suppress 
the growth of glioma tumors.
Unmodified stem cell therapy
NSCs have been shown to mobilize and juxtapose themselves 
along aggressively advancing tumor cells.10 Glass et al 
demonstrated that endogenous neural precursors migrated 
from the SVZ toward a tumor mass and surrounded the bulk 
of the tumor in an established intracranial glioma mouse 
model. Furthermore, endogenous neural precursor cells 
did not manifest a pathotropic movement when implanted 
with other non-neoplastic lesions, which suggests a specific 
tropism toward brain tumors. Unmodified NSCs that were 
cocultured with glioblastoma multiform cells showed both 
a suppression of tumor growth and an induction of tumor 
cell apoptosis in mice, which improved their survival.62 
Another previous study has provided evidence of the 
antitumor activity of NSCs and showed their migration 
toward tumor cells.63
Staflin et al showed that transplanted neural progenitor 
cells respond to queues from a tumor, home to, and 
exert an antitumor effect on the pre-established glioma. 
Transplanted NSCs significantly decreased the tumor 
volume by approximately 67% compared to untreated, 
control tumors after 1 to 2 weeks. Furthermore, these early 
effects could be translated into increased survival times of 
the animals treated with neural progenitor cell grafts 3 days 
after intrastriatal tumor injection. In contrast, there was no 
activation or migration of endogenous SVZ neuroblasts in 
response to intrastriatal syngeneic tumors. They concluded Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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that neuronal precursor cells possess the ability to influence 
tumor growth and respond to queues from the tumor or 
tumor microenvironment, thereby demonstrating cross-talk 
between the cells.64
To evaluate whether the increased survival that was 
observed after inoculation of MSC-IL2 or MSC was 
associated with the inhibition of tumor growth, Nakamura 
et al monitored tumor growth volume by magnetic resonance 
imaging (MRI) every 7 days after intracranial injection of 
tumors. The 9 L glioma was clearly visible as an enhanced 
area in the coronal section of the brain. Fourteen days 
after tumor inoculation, glioma growth progression was 
observed in the brain of untreated rats and reached a lethal 
volume. In contrast, significantly smaller tumor volumes 
were present in brains of animals treated with MSC-IL2 
or unmodified MSCs (P , 0.01, compared with untreated 
controls 14 days after tumor inoculation). A significant 
difference in tumor volume was not observed between the 
groups treated with unmodified MSCs and MSCs-IL2s by 
day 14; however, the therapeutic effect of MSCs expressing 
IL-2 was clearly visible by MRI 21 days after tumor injection. 
At this time, tumors treated with unmodified MSCs had 
reached near-lethal volumes, but those tumors treated with 
IL-2-expressing MSCs resulted in smaller tumors. The 
observed changes in glioma tumor volume were consistent 
with the survival durations in the different treatment groups. 
The prolonged survival in glioma-bearing rats treated in this 
way might depend on a direct antitumor effect of the MSCs 
themselves.48
It has been reported that in the cerebral infarction model, 
implanted MSCs mediate neural protection through the 
inhibition of neuronal apoptosis, and this protective effect 
is thought to be due to neurotrophic factors, such as nerve 
growth factor (NGF), which are released from MSCs.65 The 
protective effect of MSCs on normal brain parenchyma may 
also contribute to prolonged survival of glioma-bearing rats 
treated by MSC implantation.66
MSCs generate several neurotrophic factors, including 
NGF, which can induce differentiation and growth inhibition 
of rat glioma cells in vitro.48,67 Kang et al demonstrated 
another cytotoxic mechanism of rat MSCs, which involved 
the differentiation of rat MSCs into immune effector cells;68 
however, differentiation of hUCB-derived MSCs into 
immune effector cells has not been demonstrated, although 
a variety of cytokines could activate these cells.69
MSCs have been found to secrete large amounts of angio-
genic factors, such as angiopoietin-1 (Ang1). Ang1 
inhibits tumor-vascular leakage and tumor growth 
in vivo.70 Ang1 released from MSCs influences the antitumor 
effects of MSCs. Ang1 may also protect brain parenchyma 
from lethal cerebral edema via suppression of vascular 
leakage. MSCs mainly localize between the edge of the 
tumor and normal parenchyma and make a capsule-like 
structure. This capsule-like structure of MSCs may act as a 
barrier that prevents the spread of glioma cells into normal 
parenchyma. Thus, implantation of MSCs may be beneficial 
for the treatment of gliomas both because of their antitumor 
effects and their protective effects on normal brain 
tissue.66
Pisati et al evaluated tumor targeting and anti-tumor 
activity of human skin-derived stem cells (hSDSCs). This 
group showed that when hSDSCs were injected directly 
into glioblastomas in mice, the hSDSCs distributed them-
selves throughout the tumor mass and reduced tumor 
vessel density and angiogenic sprouts. The hSDSCs also 
differentiated into pericyte cells and produced high levels 
of human actor-β1 with low expression of VEGF, all of 
which may decrease tumor growth and prolong animal 
survival.67
The ability of hUCBs to inhibit established intracranial 
tumors was observed by Gondi et al The results of this study 
demonstrated that hUCBs are capable of inducing apoptosis 
in human glioma cells.34,41
Endogenous stem cells
Many observations have shown that brain lesions and 
neurological diseases trigger neural stem/progenitor cell 
activation and migration toward the pathological structures. 
Normal NSCs exhibit a high degree of motility throughout 
the brain after xenograft injection.26,27 In fact, the results 
of one study indicate that endogenous precursor cells are 
attracted by tumor cells, the presence of precursor cells 
is anti-tumorigenic, and this cellular interaction decreases 
with age.62
The factors implicated in such cell migrations and 
  recruitments are just beginning to be understood. Some 
factors have been reported to enhance stem cell migration 
toward   glioblastoma cells, such as transmembrane protein 18, 
MCP-1, MIP-1, and IL-8.50,71 These factors and ischemic 
cerebral tissue enhance human bone marrow stromal cell 
migration in interface culture.50,53
A recombinant human TGF-β1 fusion protein with a 
collagen-binding domain promotes migration, growth, and 
differentiation of bone marrow mesenchymal cells.50Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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It has long been considered that inflammation is largely 
devastating for brain repair, and it is now known to produce 
some positive effects on stem/progenitor cell recruitment via 
the regulation of growth factor signaling and the secretion 
of a number of chemoattractant cytokines. This knowledge 
is crucial for the development of new therapeutic strategies. 
One of these strategies could consist of increasing the 
mobilization of endogenous progenitor cells that could 
replace lost cells and improve functional recovery. It is 
not yet known why newly added neurons do not originate 
directly in the place in which they need to be located. 
Progenitor cell migration may provide an additional level 
of control for cell positioning, and the preservation of stem 
cell niches also represents a potential source of cells for 
brain repair. Yet, this may be costly for the organism, and 
it also requires specific features that restrict the structures 
to locations where they can persist. This idea implies that 
cells need to be able to migrate from these discrete niches 
to their final destinations.19
Concluding remarks
Summary
In this review, we concentrated on stem cell migration 
toward glioma tumors and provided some suggested 
mechanisms by which these stem cells may suppress 
tumor growth. Brain lesions, tumors, and neurological 
diseases trigger migration of neural stem cell/progenitor 
cells toward these altered structures. An understanding 
of the factors involved in to such cell migration events 
is a necessary step in delineating the critical pathways 
that control NSC tropism. The factors that are involved in 
migration of NSCs can be divided into two main groups: 
chemoattractant cytokines, including HGF, EGF, VEGF, 
TGF, FGF, PDGF, MPC-1, IL-8, IL-4, and   SDF-1a15,35–
37,41,43,49,50,72 and extracellular matrix compounds, such as 
tenascin, fibronectin, laminin, vitronectin, various types of 
collagen, and hyaluronic acid (Figure 1).2,44–47,73,74
It seems that there is selectivity of hMSCs for specific 
factors. For example, FGF and VEGF have little effect on 
hMSC migration, but PDGF, EGF, and SDF-1a enhance 
hMSC tropism.15
While the mechanisms by which modified stem cells 
suppress tumor growth are more often studied (see Achanta 
et al14), the precise mechanisms by which unmodified stem 
cells suppress tumor growth are not completely understood.
We suppose that biochemical immunological and   physical 
effects are responsible for growth inhibition of glioma tumor. 
A few mechanisms are suggested in some reports, including 
the following (Figure 2):
1.  Differentiation and growth inhibition of glioma cells 
in vitro, which may be due to the production of NGF by 
the MSCs.48,65,75
2.  A cytotoxic mechanism that involves the differentiation 
of rat MSCs into immune effector cells.68,69
3.  Apoptosis, in which hUCBs may be capable of inducing 
apoptosis in human glioma cells.34,41,76
4.  Inhibition of tumor growth and vascular leakage, which 
may be caused by the production of Ang1.70 Ang1 may 
also protect the brain parenchyma from lethal cerebral 
edema by reducing vascular leakage.48,70 Ang1 inhibits 
tumor-vascular leakage and tumor growth in vivo.70
5.  Formation of a barrier in which MSCs may prevent the 
spread of glioma cells into normal parenchyma.48
Future insights
An increasing knowledge about the factors that are 
necessary for stem cell survival, attraction, and their 
  interactions with the tumor environment is necessary for the 
development of rational therapeutic strategies using stem 
cell technology.2 Some of the following issues should be 
considered in further studies of cell-based therapies for the 
treatment of tumors:
1.  Stem cell type: we are currently performing the 
experiments necessary to determine whether there is any 
difference in the potency of tumor growth suppression 
and tropism among multiple types of stem cells.
2.  Factors that induce stem cell migration: different factors 
may have varying effects on the tropism of different types 
of stem cells.
Stem cell migration toward glioma tumor
Inducing factors 
Chemo-
attractant cytokines
Extra-cellular 
matrix
HGF, EGF, VEGF, 
PDGF, MPC-1
Tenascin, fibronectin, 
laminin, vitronectin
Figure 1 Stem cell migration is related to two groups of inducing factors of chemo-
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3.  Timing of the effect: there was no significant differ-
ence in tumor volume between groups treated with 
unmodified MSCs and IL-2-expressing MSCs after 
14 days of treatment. The therapeutic effect of the 
IL-2 gene   modification was, however, clearly visible by 
MRI 21 days after tumor inoculation.15
4.  Route of administration: importantly, regional   delivery of 
IFN-β-expressing hMSCs by injection into the internal 
carotid artery significantly extended the survival of 
animals harboring established intracranial gliomas. 
  Conversely, intravenous injection of IFN-β did not extend 
animal survival.15
5.  Dose dependency of antitumor effects: the most 
appropriate dose of stem cells for treatment of tumors 
remains unknown and needs to be studied. Nakamizo et al 
estimate that at least 25% of the cells (2.5 × 105) must 
have integrated into the tumor for a significant effect to 
be observed on tumor growth suppression.15
6.  Endogenous production of stem cells: considering that 
  normal stem cells exhibit a high degree of   motility through-
out the brain, and that tumor cells attract   endogenous pre-
cursor cells, this innate behavior of endogenous NSCs may 
be helpful for suppressing tumor growth. If this is true, 
enhancing the endogenous   production of stem cells may 
be a considerable issue for further studies.
7.  Neutralization of the growth-inhibitory components of 
endogenous neuronal stem cells: this may help to increase 
the capacity of attraction.
8.  Microenvironmental changes: chemical,77 physical, 
and mechanical interactions can affect the ECM, and 
cell growth and differentiation can be normalized by 
modulating cell adhesion to the ECM. Embryonic tissues 
may reverse cancerous growth by restoring these normal 
microenvironmental cues,78 and it is possible that the 
migration of either endogenous or exogenous stem cells 
toward gliomas may change the microenvironment and 
suppress tumor growth.
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